Each is fine on a normal day
My Approach When Prescribing Here's my general framework not a rigid protocol, but a starting point for the conversation: I Tend to Start with Semaglutide When The patient has established cardiovascular disease (because of the SELECT trial data) Insurance covers semaglutide but not tirzepatide The patient has MASH/fatty liver disease Cost is the primary concern and semaglutide is more accessible I Tend to Start with Tirzepatide When Maximum weight loss is the primary goal The patient has type 2 diabetes (tirzepatide shows greater A1C reduction roughly 2.02.5% vs 1.02.0% for semaglutide) The patient has tried semaglutide with insufficient results Insurance covers both options equally Regardless of which medication we choose, I always emphasize that GLP-1 therapy is most effective when combined with nutritional counseling, physical activity, and behavioral support
Mechanistically, TH have been shown to suppress hepatic fibrosis by inhibiting SMAD2/3 phosphorylation within the TGF- signaling pathway, thereby downregulating fibrosis-associated gene expression (34)
Lemon Bottle is formulated with quality natural ingredients selected for their complementary fat-reduction, anti-inflammatory and metabolic activation properties offering effective results within a well-tolerated treatment profile
They are not redundant because they work through different pathways
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
